yttrium(90Y)anditixafortide ([90Y]Y-PentixaTher) / Pentixapharm - LARVOL DELTA

Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma. (PubMed, Clin Nucl Med) - "CXCR4-directed RLT exerted relevant myeloablative effects. When performing HSCT after applying additional CON, successful neutrophile engraftment was reached in the vast majority of the cases."

Journal • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation • CXCR4

Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma. (PubMed, Clin Nucl Med) - "CXCR4-directed RLT exerted relevant myeloablative effects. When performing HSCT after applying additional CON, successful neutrophile engraftment was reached in the vast majority of the cases."

Journal • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation • CXCR4

[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: Pentixapharm AG | Trial completion date: Apr 2026 ➔ Mar 2028 | Trial primary completion date: Dec 2025 ➔ Sep 2027

Trial completion date • Trial primary completion date • CNS Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Secondary Central Nervous System Lymphoma

First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher) (PharmiWeb) - "Pentixapharm AG...has announced that a first patient has been treated in a dose-finding clinical phase I/II study with Yttrium (90Y) anditixafortide (PentixaTher) at the University Hospital in Essen, Germany. This study, PTT101 (ClinicalTrials.Gov ID: NCT06132737), is a prospective, open-label dose-escalation, multicenter study to evaluate the safety, tolerability, biodistribution and efficacy of PentixaTher in patients with CNS lymphoma (cancer affecting the central nervous systems). PentixaTher is targeting the CXCR-4 cytokine receptor which is widely expressed in different cancer indications."

Trial status • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology